AU2002253999A1 - Ascorbic acid analogs for metalloradiopharmaceuticals - Google Patents

Ascorbic acid analogs for metalloradiopharmaceuticals

Info

Publication number
AU2002253999A1
AU2002253999A1 AU2002253999A AU2002253999A AU2002253999A1 AU 2002253999 A1 AU2002253999 A1 AU 2002253999A1 AU 2002253999 A AU2002253999 A AU 2002253999A AU 2002253999 A AU2002253999 A AU 2002253999A AU 2002253999 A1 AU2002253999 A1 AU 2002253999A1
Authority
AU
Australia
Prior art keywords
metalloradiopharmaceuticals
ascorbic acid
acid analogs
analogs
ascorbic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002253999A
Other languages
English (en)
Inventor
Shuang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of AU2002253999A1 publication Critical patent/AU2002253999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2002253999A 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals Abandoned AU2002253999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27138901P 2001-02-26 2001-02-26
US60/271,389 2001-02-26
PCT/US2002/005155 WO2002067859A2 (en) 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals

Publications (1)

Publication Number Publication Date
AU2002253999A1 true AU2002253999A1 (en) 2002-09-12

Family

ID=23035343

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002253999A Abandoned AU2002253999A1 (en) 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals

Country Status (12)

Country Link
US (1) US6713042B2 (https=)
EP (1) EP1365813A4 (https=)
JP (1) JP2004529884A (https=)
CN (1) CN1503680A (https=)
AU (1) AU2002253999A1 (https=)
BR (1) BR0207315A (https=)
CA (1) CA2438204A1 (https=)
CZ (1) CZ20032597A3 (https=)
HU (1) HUP0304083A2 (https=)
IL (1) IL157359A0 (https=)
MX (1) MXPA03007595A (https=)
WO (1) WO2002067859A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
US20050089470A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled peptides for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20050089471A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled ligands for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
US8303935B2 (en) * 2006-05-19 2012-11-06 Nihon Medi-Physics Co., Ltd. Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid
WO2007148755A1 (ja) * 2006-06-21 2007-12-27 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物
CA2654369C (en) * 2006-06-21 2014-10-14 Ge Healthcare Limited Radiopharmaceutical products
US20100056826A1 (en) * 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
US20090252680A1 (en) * 2006-11-17 2009-10-08 Nihon- Medi-Physics Co., Ltd Novel compound with affinity for amyloid
CA2670436A1 (en) * 2006-11-30 2008-06-05 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
PT2106808T (pt) * 2006-12-21 2018-03-26 Nihon Mediphysics Co Ltd Agente de imagiologia de diagnóstico radioativo compreendendo ácido 1-amino-3-[18f]fluoro-ciclobutanocarboxílico
JP5258583B2 (ja) 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
KR20100091965A (ko) * 2007-10-24 2010-08-19 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
EP2216052A4 (en) * 2007-10-30 2012-11-21 Nihon Mediphysics Co Ltd USE OF A NEW COMPOUND WITH AFFINITY FOR AMYLOID AND METHOD FOR THE PRODUCTION THEREOF
WO2009057576A1 (ja) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物の使用及び製造方法
CA2706111C (en) * 2007-12-04 2013-06-18 Bracco Imaging S.P.A. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
RU2011112946A (ru) * 2008-09-05 2012-10-10 Молекьюлар Инсайт Фармасьютикалз, Инк. (Us) Фармацевтическая композиция радиойодированного бензамидного производного и способы ее получения
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
KR20160030589A (ko) 2009-04-15 2016-03-18 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
WO2013093099A1 (en) * 2011-12-22 2013-06-27 Piramal Imaging Sa Stabilization of peptidic radiopharmaceuticals using uric acid or derivatives thereof
WO2013176522A1 (ko) * 2012-05-24 2013-11-28 서강대학교산학협력단 카트리지를 이용한 방사성의약품 제조방법
US20140147381A1 (en) * 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
CA2901231C (en) * 2013-02-15 2020-06-23 Thomas Jefferson University Kit comprising lyophilized compositions for tumor imaging
JP6500105B2 (ja) * 2014-11-27 2019-04-10 セルトリオン・インコーポレイテッド ペプチドが結合された安定したアスコルビン酸誘導体、その製造方法、及びそれを含む化粧料組成物
TWI604853B (zh) * 2016-05-03 2017-11-11 行政院原子能委員會核能研究所 放射免疫複合體、診療劑及套組
CN107167540B (zh) * 2017-07-08 2019-07-30 万舒（北京）医药科技有限公司 测定人尿液生物样品中的DTPA-Zn的方法
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL42204A (en) * 1972-05-08 1976-09-30 Solco Basel Ag Process and apparatus for the manufacture of injectable radionuclide preparations
US4504462A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
DE69007229T2 (de) * 1989-10-09 1994-06-16 Unilever Nv Verfahren zur Herstellung von essbaren Aufstrichen und Anlage dafür.
DK0600992T3 (da) * 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
AU2526497A (en) * 1996-02-02 1997-08-22 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
CA2413538A1 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof

Also Published As

Publication number Publication date
US20020122769A1 (en) 2002-09-05
HUP0304083A2 (hu) 2004-03-29
BR0207315A (pt) 2004-02-10
EP1365813A2 (en) 2003-12-03
CN1503680A (zh) 2004-06-09
WO2002067859A2 (en) 2002-09-06
US6713042B2 (en) 2004-03-30
JP2004529884A (ja) 2004-09-30
EP1365813A4 (en) 2006-03-22
IL157359A0 (en) 2004-02-19
WO2002067859A3 (en) 2002-11-28
CZ20032597A3 (cs) 2004-12-15
MXPA03007595A (es) 2003-12-04
CA2438204A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
AU2002253999A1 (en) Ascorbic acid analogs for metalloradiopharmaceuticals
AU2002349297A1 (en) Statin-like compounds
AU2002253675A1 (en) Chromene compound
AU2002360487A1 (en) Acyclovir-peptide analogs
AU2002357602A1 (en) Adsorbent for phosphoric acid
AU2002349677A1 (en) Chromene compound
AU2002350942A1 (en) Imidazolidineacetic acid derivatives
AU2002310684A1 (en) Vitamin D analogues
AU2001296775A1 (en) Triptycene analogs
PL366980A1 (en) Hydroxyeicosenoic acid analogs
AU2002329931A1 (en) Salvianolic acid b
AU6550800A (en) Hepoxilin analogs
AUPR755501A0 (en) Cyclic compound
AUPR920301A0 (en) Neurologically-active compounds
AU2002342940A1 (en) New pharmaceutical compounds
AU2002366040A1 (en) Novel tetronic acid derivative
AUPR520201A0 (en) Antiviral compounds
AU2002244978A1 (en) Alpha-substituted omega-arylfatty acid derivative
AU2002361987A1 (en) Substituted beta-aminoalcohols used as medicaments
AU2001285801A1 (en) 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivates
AU2002314307A1 (en) Composition containing 2-aminophenylacetic acid
AU2291600A (en) New vitamin d analogs
AU2004201666B2 (en) 4-Imidazolin-2-one compounds
AUPR738001A0 (en) Compound for medicinal purposes
AU2002347439A1 (en) Isobenzofuran derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase